Report
Niclas Gehin
EUR 433.83 For Business Accounts Only

Borregaard (Buy, TP: NOK260.00) - Vanillin and Exilva set for growth

In our view, Borregaard’s valuation reflects the market’s appetite for bio-based and ESG-friendly products, and our SOTP assumes substantial growth potential for vanillin and Exilva. We have raised our 2022e EPS by 14%, and find the stock attractively valued at a 2022e EV/EBITDA of 14.2x. We have thus upgraded to BUY (HOLD) and lifted our target price to NOK260 (215).
Underlying
Borregaard

Borregaard is a supplier of specialized biochemicals for a global customer base. Co.'s main products are lignin-based products and specialty cellulose, but its product portfolio also extends to vanillin, bioethanol and fine chemicals. Co.'s products serve applications in a range of global end-markets including construction, agriculture, food and beverages, transportation and pharmaceuticals. Co.'s business model is closely linked to the integrated nature of its biorefinery in Norway, which utilizes the wood components to produce a portfolio of products. Co. operates in three business segments: Performance Chemicals, Specialty Cellulose and Other Businesses.

Provider
DnB Markets
DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

 

Analysts
Niclas Gehin

Other Reports on these Companies
Other Reports from DnB Markets
Alexander Aukner
  • Alexander Aukner
Alexander Aukner
  • Alexander Aukner
Alexander Aukner
  • Alexander Aukner

ResearchPool Subscriptions

Get the most out of your insights

Get in touch